The clinical and diagnostic utility of S100B in preterm newborns

Laura D. Serpero, Francesca Pluchinotta, Diego Gazzolo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Preterm birth is still the most important cause of perinatal mortality and morbidity. Follow-up studies showed that the majority of neurological abnormalities during childhood are already present in the first week after birth. In this light, the knowledge of the timing of the insult and/or of the contributing factors is of utmost relevance in order to avoid adverse neurological outcome. Notwithstanding, the considerable advances in perinatal clinical care and monitoring, the early detection of cases at risk for brain damage is still a challenge because, when radiological pictures are still negative, brain damage may be already at a subclinical stage, with symptoms hidden by therapeutic strategies. Thus, it could be very relevant to measure quantitative parameters, such as neuroproteins, able to detect subclinical lesions at a stage when routine brain monitoring procedures are still silent.In the last decade, the assay of the brain-specific protein S100B in different biological fluids proved useful information on brain function and damage in the perinatal period.Therefore, the present study provides an overview of the most recent findings on S100B role as a reliable marker of brain development/damage in preterm high risk fetuses and newborns.

Original languageEnglish
Pages (from-to)193-198
Number of pages6
JournalClinica Chimica Acta
Volume444
DOIs
Publication statusPublished - Apr 5 2015

Fingerprint

Brain
Newborn Infant
Perinatal Care
Monitoring
Perinatal Mortality
Premature Birth
Assays
Fetus
Parturition
Morbidity
Fluids
Proteins
Therapeutics

Keywords

  • Brain damage
  • Congenital heart diseases
  • Fetus
  • Hypoxia
  • Newborn
  • S100B

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

The clinical and diagnostic utility of S100B in preterm newborns. / Serpero, Laura D.; Pluchinotta, Francesca; Gazzolo, Diego.

In: Clinica Chimica Acta, Vol. 444, 05.04.2015, p. 193-198.

Research output: Contribution to journalArticle

Serpero, Laura D. ; Pluchinotta, Francesca ; Gazzolo, Diego. / The clinical and diagnostic utility of S100B in preterm newborns. In: Clinica Chimica Acta. 2015 ; Vol. 444. pp. 193-198.
@article{4890600963254992afc95bf568cc6d87,
title = "The clinical and diagnostic utility of S100B in preterm newborns",
abstract = "Preterm birth is still the most important cause of perinatal mortality and morbidity. Follow-up studies showed that the majority of neurological abnormalities during childhood are already present in the first week after birth. In this light, the knowledge of the timing of the insult and/or of the contributing factors is of utmost relevance in order to avoid adverse neurological outcome. Notwithstanding, the considerable advances in perinatal clinical care and monitoring, the early detection of cases at risk for brain damage is still a challenge because, when radiological pictures are still negative, brain damage may be already at a subclinical stage, with symptoms hidden by therapeutic strategies. Thus, it could be very relevant to measure quantitative parameters, such as neuroproteins, able to detect subclinical lesions at a stage when routine brain monitoring procedures are still silent.In the last decade, the assay of the brain-specific protein S100B in different biological fluids proved useful information on brain function and damage in the perinatal period.Therefore, the present study provides an overview of the most recent findings on S100B role as a reliable marker of brain development/damage in preterm high risk fetuses and newborns.",
keywords = "Brain damage, Congenital heart diseases, Fetus, Hypoxia, Newborn, S100B",
author = "Serpero, {Laura D.} and Francesca Pluchinotta and Diego Gazzolo",
year = "2015",
month = "4",
day = "5",
doi = "10.1016/j.cca.2015.02.028",
language = "English",
volume = "444",
pages = "193--198",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - The clinical and diagnostic utility of S100B in preterm newborns

AU - Serpero, Laura D.

AU - Pluchinotta, Francesca

AU - Gazzolo, Diego

PY - 2015/4/5

Y1 - 2015/4/5

N2 - Preterm birth is still the most important cause of perinatal mortality and morbidity. Follow-up studies showed that the majority of neurological abnormalities during childhood are already present in the first week after birth. In this light, the knowledge of the timing of the insult and/or of the contributing factors is of utmost relevance in order to avoid adverse neurological outcome. Notwithstanding, the considerable advances in perinatal clinical care and monitoring, the early detection of cases at risk for brain damage is still a challenge because, when radiological pictures are still negative, brain damage may be already at a subclinical stage, with symptoms hidden by therapeutic strategies. Thus, it could be very relevant to measure quantitative parameters, such as neuroproteins, able to detect subclinical lesions at a stage when routine brain monitoring procedures are still silent.In the last decade, the assay of the brain-specific protein S100B in different biological fluids proved useful information on brain function and damage in the perinatal period.Therefore, the present study provides an overview of the most recent findings on S100B role as a reliable marker of brain development/damage in preterm high risk fetuses and newborns.

AB - Preterm birth is still the most important cause of perinatal mortality and morbidity. Follow-up studies showed that the majority of neurological abnormalities during childhood are already present in the first week after birth. In this light, the knowledge of the timing of the insult and/or of the contributing factors is of utmost relevance in order to avoid adverse neurological outcome. Notwithstanding, the considerable advances in perinatal clinical care and monitoring, the early detection of cases at risk for brain damage is still a challenge because, when radiological pictures are still negative, brain damage may be already at a subclinical stage, with symptoms hidden by therapeutic strategies. Thus, it could be very relevant to measure quantitative parameters, such as neuroproteins, able to detect subclinical lesions at a stage when routine brain monitoring procedures are still silent.In the last decade, the assay of the brain-specific protein S100B in different biological fluids proved useful information on brain function and damage in the perinatal period.Therefore, the present study provides an overview of the most recent findings on S100B role as a reliable marker of brain development/damage in preterm high risk fetuses and newborns.

KW - Brain damage

KW - Congenital heart diseases

KW - Fetus

KW - Hypoxia

KW - Newborn

KW - S100B

UR - http://www.scopus.com/inward/record.url?scp=84923324992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923324992&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2015.02.028

DO - 10.1016/j.cca.2015.02.028

M3 - Article

VL - 444

SP - 193

EP - 198

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -